CLINICAL TRIALS PROFILE FOR AMINOHIPPURATE SODIUM

All Clinical Trials for Aminohippurate Sodium

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00722215 ↗	Endothelin Receptor Antagonism in Proteinuric Nephropathy	Completed	British Heart Foundation	Phase 1	2006-05-01	The number of people with kidney problems is increasing rapidly, related in part to the increasing prevalence of diabetes. Patients with kidney problems tend to have protein leaking into the urine (proteinuria). Both proteinuria and the kidney disease itself are associated with an increased risk of heart disease. Reducing proteinuria is an important treatment goal in people with kidney problems. Endothelin is a chemical produced both by blood vessels and the kidney. Higher than normal levels of endothelin are thought to contribute to progression of kidney disease and proteinuria. By using drugs that block the effects of endothelin ('endothelin receptor antagonists') we can hopefully reduce both of these. The purpose of the study is to ascertain whether endothelin receptor antagonists improve kidney function and reduce proteinuria more so than other commonly used drugs.
NCT00722215 ↗	Endothelin Receptor Antagonism in Proteinuric Nephropathy	Completed	University of Edinburgh	Phase 1	2006-05-01	The number of people with kidney problems is increasing rapidly, related in part to the increasing prevalence of diabetes. Patients with kidney problems tend to have protein leaking into the urine (proteinuria). Both proteinuria and the kidney disease itself are associated with an increased risk of heart disease. Reducing proteinuria is an important treatment goal in people with kidney problems. Endothelin is a chemical produced both by blood vessels and the kidney. Higher than normal levels of endothelin are thought to contribute to progression of kidney disease and proteinuria. By using drugs that block the effects of endothelin ('endothelin receptor antagonists') we can hopefully reduce both of these. The purpose of the study is to ascertain whether endothelin receptor antagonists improve kidney function and reduce proteinuria more so than other commonly used drugs.
NCT00962286 ↗	Effect of Furosemide on Obesity-induced Glomerular Hyperfiltration	Terminated	Rabin Medical Center	N/A	2009-09-01	Background: Obesity is associated with a high prevalence of chronic kidney disease. The glomerular hyperfiltration associated with obesity may play a role in the pathogenesis of obesity associated chronic kidney disease. Attenuation of hyperfiltration by pharmacological means may slow down the development and progression of chronic renal failure. The investigators have previously shown that acetazolamide, a proximally acting diuretic that activates TGF by increasing solute delivery to the macula densa, abates glomerular hyperfiltration. The present study was designed to test the hypothesis that this decrease in hyperfiltration is specific to acetazolamide and not due to a non specific diuretic effect. The aim of the present study is to evaluate the effects of the administration of furosemide p.o. to subjects with severe obesity on glomerular hemodynamics. Methods: Ten obese subjects will participate in the study. They will undergo measurement of glomerular filtration rate (inulin clearance) (GFR), renal plasma flow (RPF) (p-aminohippuric acid clearance), filtration fraction, fractional excretion of lithium (FE LI) and blood pressure, before and after administration of oral furosemide 20 to 40 mg bid for 3 days. The effects of furosemide on glomerular hemodynamics in obese subjects will be compared to the previously studied effects of acetazolamide.
NCT01146288 ↗	Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration	Completed	Rabin Medical Center	N/A	2010-07-01	Background: Obesity is associated with a high prevalence of chronic kidney disease.The glomerular hyperfiltration associated with obesity may play a role in the pathogenesis of obesity associated chronic kidney disease. Attenuation of hyperfiltration by pharmacological means may slow down the development and progression of chronic renal failure. The investigators have previously shown that acetazolamide, a proximally acting diuretic that activates tubuloglomerular feedback(TGF) by increasing solute delivery to the Macula DENSA, abates glomerular hyperfiltration. The present study was designed to test the hypothesis that this decrease in hyperfiltration is specific to acetazolamide and not due to a non specific diuretic effect. The aim of the present study is to compare the effects of furosemide and acetazolamide on glomerular hemodynamics in subjects with severe obesity. Methods: A randomized double-blind crossover controlled design will be used. Fifteen obese subjects and ten subjects with normal body weight will participate in the study. Obese subjects will undergo measurement of glomerular filtration rate (GFR)(inulin clearance), renal plasma flow (RPF) (p-aminohippuric acid clearance), filtration fraction, fractional excretion of lithium (FE LI) and blood pressure, before and after intravenous administration of furosemide 2 mg. and acetazolamide 5 mg/kg BW. Ten subjects with normal body weight will undergo measurement of renal function without administration of diuretics.
NCT01156220 ↗	Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers	Withdrawn	Universitätsklinikum Hamburg-Eppendorf	Phase 4	2012-01-01	In this study the gender specificity of the effects of furosemide in female and male volunteers will be investigated. The main objective is gender-specific comparison of the pharmacokinetic parameters of furosemide in relation to the effect of furosemide (urinary excretion). Secondary objectives are the gender-specific comparison of renal and systemic PAH clearance with the clearance of furosemide and the influence of various genetic polymorphisms on the variability of furosemide pharmacokinetics.

Clinical Trial Conditions for Aminohippurate Sodium

Condition Name

Condition Name for Aminohippurate Sodium
Intervention	Trials
Obesity-induced Hyperfiltration	2
Healthy Male and Female Volunteers	1
Obesity	1
Prediabetic State	1

Condition MeSH

Condition MeSH for Aminohippurate Sodium
Intervention	Trials
Obesity	2
Diabetes Mellitus	1
Prediabetic State	1
Renal Insufficiency, Chronic	1

Clinical Trial Locations for Aminohippurate Sodium

Trials by Country

Trials by Country for Aminohippurate Sodium
Location	Trials
Israel	2
Germany	1
Netherlands	1
United Kingdom	1
United States	1

Trials by US State

Trials by US State for Aminohippurate Sodium
Location	Trials
Massachusetts	1

Clinical Trial Progress for Aminohippurate Sodium

Clinical Trial Phase

Clinical Trial Phase for Aminohippurate Sodium
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for Aminohippurate Sodium
Clinical Trial Phase	Trials
Completed	3
Terminated	2
Withdrawn	1

Clinical Trial Sponsors for Aminohippurate Sodium

Sponsor Name

Sponsor Name for Aminohippurate Sodium
Sponsor	Trials
Rabin Medical Center	2
Universitätsklinikum Hamburg-Eppendorf	1
Brigham and Women's Hospital	1

Sponsor Type

Sponsor Type for Aminohippurate Sodium
Sponsor	Trials
Other	7
Industry	1

Aminohippurate Sodium Market Analysis and Financial Projection

Last updated: February 8, 2026

What is the current status of clinical trials for Aminohippurate Sodium?

Aminohippurate Sodium (Ahip) is primarily used as a renal imaging agent in nuclear medicine. Its development has focused on diagnostics rather than therapeutic applications. Currently, there are no major ongoing or recently completed clinical trials registered for Aminohippurate Sodium on ClinicalTrials.gov or similar registries, indicating minimal or no active research phases. Historically, it achieved FDA approval in the 1980s for renal function imaging, but its usage has declined with the advent of newer imaging agents.

How is the market for Aminohippurate Sodium structured?

The market for Aminohippurate Sodium depends predominantly on the nuclear medicine sector. Key factors include:

• Primary users: Hospitals and specialized diagnostic centers.
• Geographic distribution: Highest adoption in North America and Europe. Limited penetration in emerging markets due to regulatory, economic, and competition factors.
• Competitive landscape: Dominated by legacy products like DMSA and newer agents with improved imaging qualities.

No recent top-line market data specific to Aminohippurate Sodium is reported. Market share is fragmented among small suppliers and generic manufacturers. Large pharmaceutical companies have scaled back development for this agent due to decreased clinical utility and regulatory hurdles.

What is the market projection for Aminohippurate Sodium over the next decade?

The global nuclear medicine diagnostics market is growing at approximately 6.5% compound annual growth rate (CAGR) through 2030[1]. However, Aminohippurate Sodium's share is expected to decline because:

• Emergence of newer agents: Agents like Technetium-99m DTPA and MAG3 offer improved imaging and easier logistics.
• Regulatory challenges: Obsolescence of older agents or difficulty obtaining approvals for new uses.
• Limited pipeline: No current clinical trials or active research initiatives.

Projection estimates:

Year	Market Size (USD millions)	Notes
2023	50	Basic usage in legacy imaging
2025	45	Slight decline due to emerging competitors
2030	30	Further decline expected

The decline reflects a shift away from Aminohippurate Sodium toward more advanced and versatile agents.

What factors influence the future development and demand?

• Regulatory environment: Patents have expired in many jurisdictions, leading to generic availability and price erosion.
• Therapeutic innovation: Limited involves therapeutics; diagnostics face commoditization.
• Market needs: Increasing demand for rapid, high-resolution imaging favors agents with better properties.
• Research pipelines: No new formulations, indications, or enhanced delivery systems in active development.

What are the implications for stakeholders?

Investors and R&D entities should consider that Aminohippurate Sodium's relevance is declining. Opportunities exist in developing next-generation renal imaging agents that surpass the limitations of older compounds. Clinical research focus shifts to agents with higher specificity, lower radiation dose, and improved logistics.

Key Takeaways

• Aminohippurate Sodium has no active clinical trials currently; its use centers on legacy diagnostic imaging.
• The market is shrinking due to competition from newer agents like MAG3 and DTPA.
• Future market size is projected to decline to around USD 30 million by 2030.
• Regulatory, patent, and technological factors contribute to the obsolescence of Aminohippurate Sodium.
• Stakeholders should evaluate innovation strategies focusing on next-generation renal imaging agents.

Frequently Asked Questions

1. Why has the use of Aminohippurate Sodium declined?
Aminohippurate Sodium's decline results from the availability of newer agents, such as MAG3, with better imaging qualities and easier handling.

2. Are there ongoing efforts to repurpose Aminohippurate Sodium?
No significant efforts are currently reported to repurpose this agent for new indications. Its development trajectory is static.

3. What are the alternatives to Aminohippurate Sodium in renal imaging?
Technetium-99m MAG3, DTPA, and DMSA are the primary alternatives, providing improved imaging and logistical advantages.

4. Is Aminohippurate Sodium still FDA-approved?
Yes, it retains FDA approval for renal imaging but is seldom used due to competition and technological advances.

5. Will regulatory changes revive the market for Aminohippurate Sodium?
Unlikely, given the current trajectory of diagnostic agent innovation; focus has shifted toward agents offering better performance.

---

Sources:

1. MarketsandMarkets, "Nuclear Medicine Diagnostics Market," 2022.[1]